Merck's Keytruda nabs melanoma nod in EU; AstraZeneca's MEK inhibitor fails late-stage melanoma trial;

> Merck ($MRK) won European approval for its closely watched cancer immunotherapy Keytruda, for use in patients with advanced melanoma who haven't yet been treated or who've failed on previous therapy; the drug won U.S. approval last year. Release

> AstraZeneca ($AZN) said its new cancer treatment selumetinib, a MEK inhibitor, fell short in a Phase III trial in uveal melanoma patients; testing is ongoing in a variety of other cancer types. Release

> With HIV treatments readily available in low-income countries, Doctors Without Borders is shifting its attention to broadening access to the meds in middle-income countries where cut-rate generic programs don't apply. Release

> Patients using the diabetes drugs Avandia (rosiglitazone) and Actos (pioglitazone) had a 28% lower incidence of Parkinson's disease, a study found; researchers said the results should prompt new studies into the drugs' mechanisms. Report

> Merck broadened its nanobody medicines collaboration with Belgium-based Ablynx, adding 12 new programs and boosting the total potential milestones to about 4 billion euros. Report

And Finally... The first U.S. drug delivery by drone happened in Virginia, in a test of the technology for transporting medical supplies to remote areas. Report

Suggested Articles

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.

Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.